Cancel

Myasthenia Gravis Research Highlights: AAN 2023

This 30-minute CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction. Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently four drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, and rozanolixizumab. There are also treatments in development. Clinical tria...
CheckRare

Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs

STATEMENT OF NEED Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ...
i3 Health

Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma

STATEMENT OF NEED Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the ident...
i3 Health

Putting the Freeze on Cold Agglutinin Disease

STATEMENT OF NEED Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia (AIHA) in which antibodies cause hemolysis at cold temperatures, generally between 37º to 39º Fahrenheit. Approximately 1 in a million people are affected by CAD annually, with onset usually occurring between the ages of 40 and 80 years. Individuals commonly experience fatigue, dizziness, palpitations, and shortness of breath caused by the anemia; jaundice caused by degradation of hemoglobin i...
i3 Health

Acromegaly Research Highlights: ENDO 2023

This 30-minute CME-accredited program highlights the latest clinical research about acromegaly, a rare endocrine disorder. Common symptoms include subtle skeletal overgrowth; soft tissue swelling (tongue, heart, kidney, colon, and vocal cords); unusually prominent forehead and heavy brow ridge; protruding lower jaw; overbite; skin thickening; increased shoe and ring size; hypertension; increased perspiration; headaches; paresthesia; and sexual dysfunction. There are several orphan drugs app...
CheckRare

Duchenne Muscular Dystrophy: Recognizing Its Earliest Signs in Infancy and Care Transition into Adulthood

Target Audience The intended audience for this activity are neurologists, neuromuscular specialists, pediatric neurologists, genetic counselors, and pediatricians. Program Overview Join a panel of expert clinicians to identify the subtle and very early signs of DMD that may be detected before functional symptoms are noticed and that can help earlier diagnoses and appropriate interventions. Panelists will review the importance of matching mutations to therapeutic decisions, discuss emergin...
Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with Parent Project Muscular Dystrophy (PPMD) and the National Organization for Rare Disorders (NORD).

LET'S TALK: Tackling Complex Issues Regarding SM-AHN Management A Monday Morning Joe Online Educational Activity

Systemic mastocytosis (SM) is a group of rare disorders characterized by the accumulation of mast cells in internal tissues and organs. The pathogenesis of SM is linked to a characteristic exon 17 D816V mutation of the KIT gene. Systemic mastocytosis with associated hematologic neoplasms (SM-AHN) is an advanced subtype of SM that is associated with a shortened median survival time. Recent advances in the SM therapeutic landscape have led to the development of KIT-targeted treatment options; ho...
Integritas Communications

Current and Emerging Therapies for Follicular Lymphoma: Solving Practice Challenges in Community-Based Interprofessional Care Teams

An indolent subtype of non-Hodgkin lymphoma, follicular lymphoma is characterized by eventual relapse of disease and the need for multiple lines of therapy, adding to the significant disease burden experienced by patients. Novel targeted agents in the relapsed/refractory setting have afforded new treatment options, but important clinical challenges exist, including optimal treatment sequencing, therapy evaluation and patient selection, transitions of care requirements, as well as toxicity mana...
Annenberg Center for Health Sciences

Nurses Light the Path: Empowering Patients to Improve Breast Cancer Screening and Clinical Trial Representation

Target Audience The primary target audience for this activity is Oncology Nursing Professionals (APRN, NP, RN). Program Overview For women with breast cancer and those at risk, disparities in screening and clinical-trial enrollment exist, particularly among racial and ethnic minority populations. Awareness of these disparities can ensure timely screening practices and help address patient fears and concerns regarding clinical trials that inhibit diverse representation in research. Younger...
Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with Black Nurses Rock.

Obsessive-Compulsive Disorder (OCD)

Obsessive-Compulsive Disorder (OCD) is a 3-hour online continuing education (CE/CEU) course that reviews the diagnosis, assessment and treatment strategies for OCD. Obsessive-Compulsive Disorder (OCD) is characterized by intrusive, unwanted, and anxiety-provoking thoughts, images, impulses and rituals that are performed to alleviate the accompanying distress. Because OCD is a heterogeneous disorder with several subtypes, assessing, diagnosing, and treating it can be challenging. Further, th...
Professional Development Resources

Therapy Tidbits - September/October 2017

Therapy Tidbits – September/October 2017 is a 1-hour online continuing education (CE) course comprised of select articles from the September/October 2017 issue of The National Psychologist, a private, independent bi-monthly newspaper intended to keep mental health professionals informed about practice issues. The articles included in this course are: Practical Benefits Debatable for Geropsychology Specialty — Generalist vs specialist? This article examines which option may be a more se...
Professional Development Resources

Seven Sensory Strategies to Increase Artic-Therapy Success - Char Boshart, MA CCC-SLP

The mouth is the only body part that interacts with itself, meaningfully. And the two primary forms of that meaningful interaction (for speaking, chewing, and swallowing) are tactile and proprioceptive in nature. Wouldn’t it be helpful for a child to be able to localize his front-tongue to elevate it purposefully and consistently for t, d, s, z, sh, zh, ch, j, and l, as well as for his back-tongue for the k, g, ng, and r sound? This one-hour course demonstrates practical techniques ...
Speech Therapy Professional Development

Autism: The New Spectrum of Diagnostics, Treatment & Nutrition

Autism: The New Spectrum of Diagnostics, Treatment & Nutrition is a 4-hour online continuing education (CE/CEU) course that reviews diagnostic changes in autism as well as treatment options and nutrition interventions - both theoretical and applied. The first section traces the history of the diagnostic concept of autism spectrum disorder (ASD), culminating in the revised criteria of the 2013 version of the Diagnostic and Statistical Manual of Mental Disorders, the DSM-5, with specific focu...
Professional Development Resources

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map